RCUS — Arcus Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $2.77bn
- $1.89bn
- $247.00m
- 27
- 11
- 79
- 32
Annual cashflow statement for Arcus Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 52.8 | -267 | -307 | -283 | -353 |
| Depreciation | |||||
| Non-Cash Items | 62.8 | 76 | 64 | 81 | 55 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -376 | 623 | -71 | 22 | -194 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -256 | 438 | -306 | -170 | -482 |
| Capital Expenditures | -26.1 | -6 | -24 | -6 | -2 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 22.2 | -407 | 218 | -78 | 68 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -3.87 | -413 | 194 | -84 | 66 |
| Financing Cash Flow Items | 5 | 10 | 0 | -7 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 237 | 33 | 33 | 277 | 488 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -22.7 | 58 | -79 | 23 | 72 |